Plain-English translation of NCT05051722 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether a new blood test based on methylated DNA markers can reliably detect endometrial cancer, ovarian cancer, cervical cancer, and precancerous changes in women. Right now, when women have abnormal or postmenopausal bleeding, doctors often need to do invasive procedures like biopsies to figure out what's causing it. This study hopes the blood test could identify which women actually have cancer or precancerous changes without requiring these more invasive procedures.
Most women who experience abnormal bleeding don't have cancer—but doctors still need to do uncomfortable biopsies to rule it out. There's no simple, early detection test for these cancers like there is for cervical cancer screening. This study aims to create a blood test that could save women from unnecessary invasive procedures while catching cancers earlier, when they're easier to treat.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you may donate a blood sample when you come in for your already-scheduled appointment (such as a biopsy or colposcopy). If you have abnormal bleeding, you might provide a sample when your doctor is evaluating your symptoms. The blood test itself is simple—similar to a routine blood draw—and the study collects one sample to test for these methylated DNA markers.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States